Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 19 Carcinoma, Non-Small-Cell Lung 19 Breast Neoplasms 17 Lung Neoplasms 15 Colonic Neoplasms 11 Head and Neck Neoplasms 9 Rectal Neoplasms 7 Glioblastoma 5 Prostatic Neoplasms 4 Precancerous Conditions 4 Mouth Neoplasms 4 Esophageal Neoplasms 4 Central Nervous System Neoplasms 4 Adenomatous Polyposis Coli 4 Uterine Cervical Neoplasms 3 Unspecified Adult Solid Tumor, Protocol Specific 3 Sarcoma 3 Neuroblastoma 3 Neoplasms 3 Liver Neoplasms 3 Gliosarcoma 3 Glioma 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Smoking 2 Salivary Gland Neoplasms 2 Pancreatic Neoplasms 2 Oropharyngeal Neoplasms 2 Nasopharyngeal Neoplasms 2 Multiple Myeloma 2

Interventions

Sirolimus 6 Everolimus 5 saracatinib 1 nintedanib 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Glutamine 1 Doxycycline 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphangioleiomyomatosis × Celecoxib × Clear all

NCT02484664 2022-01-20

COLA

Brigham and Women's Hospital

Phase 2 Completed

12 enrolled 11 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡